Copyright
©The Author(s) 2003.
World J Gastroenterol. Aug 15, 2003; 9(8): 1881-1883
Published online Aug 15, 2003. doi: 10.3748/wjg.v9.i8.1881
Published online Aug 15, 2003. doi: 10.3748/wjg.v9.i8.1881
Table 1 General data in two groups
| Induction group (n = 23) | Non-induction group (n = 31) | |
| Average age(yr) | 39.17(19-68) | 38.76(11-57) |
| Male/female | 21/2 | 23/8 |
| Indication with | ||
| Liver cirrhosis | 15 | 18 |
| Liver cancer | 6 | 6 |
| Other | 2 | 7 |
| UNOS classification | ||
| Grade I | 5 | 10 |
| Grade II | 18 | 21 |
| Child classification | ||
| Grade A | 4 | 9 |
| Grade B | 2 | 0 |
| Grade C | 17 | 22 |
| Blood type | ||
| ABO-identical | 14 | 23 |
| ABO-compatible | 9 | 8 |
- Citation: Yan LN, Wang W, Li B, Lu SC, Wen TF, Lin QY, Zeng Y, Cheng NS, Zhao JC, Dai YM. Single-dose daclizumab induction therapy in patients with liver transplantation. World J Gastroenterol 2003; 9(8): 1881-1883
- URL: https://www.wjgnet.com/1007-9327/full/v9/i8/1881.htm
- DOI: https://dx.doi.org/10.3748/wjg.v9.i8.1881